A Phase 1/2 interventional study of Tislelizumab in Advanced Solid Tumors, sponsored by BeiGene. Completed at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a dose verification, pharmacokinetic (PK) assessment of products derived from two manufacturing processes and scales (500L-FMP and 2000L-FMP; FMP: Final Manufacturing Process) and indication expansion clinical study of monoclonal antibody conducted in Chinese subjects with advanced solid tumors, with a purpose of exploring the safety, tolerability, pharmacokinetics and preliminary efficacy.
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Females are eligible to participate in the study if they are:
a) Non- (that is, physiologically incapable of becoming pregnant) who:
Key Exclusion Criteria:
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tislelizumab 200 mg intravenously (IV) once every 3 weeks (21 days per cycle) until no evidence of continued clinical benefits, unacceptable toxicity, or withdrawal of informed consent at the discretion of the investigator. There were 3 parts in this study: dose verification, pharmacokinetic (PK) sub-study, and indication expansion.
Drug: Tislelizumab
Administered intravenously
Also known as: BGB-A317
Dose Verification and PK Sub-study: Number Participants With Adverse Events
Number of participants with adverse events (AEs) and serious adverse events (SAEs), as defined per NCI-CTCAE Version 4.03, including physical examination, electrocardiograms and laboratory assessments
Time frame: Up to approximately 23 months
Dose Verification: Recommended Dose of Tislelizumab
Recommended dose of tislelizumab for indication cohorts based on safety and tolerability
Time frame: Up to approximately 23 months
PK Sub-study: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tislelizumab From Two Manufacturing Processes and Scales
Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter final manufacturing process (FMP) were evaluated
Time frame: Predose, end of infusion, 3 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, and Day 29 predose
PK Sub-study: Area Under the Concentration-time Curve From Time 0 to 28 Days Postdose (AUC0-28d) of Tislelizumab From Two Manufacturing Processes and Scales
Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter final manufacturing process (FMP) were evaluated
Time frame: Predose, end of infusion, 3 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, and Day 29 predose
PK Sub-study: Maximum Observed Concentration (Cmax) of Tislelizumab From Two Manufacturing Processes and Scales
Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter FMP were evaluated
Time frame: Predose, end of infusion, 3 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22, and Day 29 predose
Indication Expansion: Objective Response Rate
Objective response rate (ORR) is defined as the percentage of participants who achieved objective tumor response (complete response or partial response) according to RECIST Version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
Time frame: Up to approximately 3 years and 5 months
Dose Verification: Area Under the Concentration-time Curve From Time 0 to 21 Days Postdose (AUC0-tau) of Tislelizumab
Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)
Dose Verification: Maximum Observed Concentration (Cmax) of Tislelizumab
Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)
Dose Verification: Predose Plasma Concentration of Tislelizumab During Multiple Dosing (Ctrough)
Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)
Dose Verification: Apparent Terminal Half-life of Tislelizumab (t1/2)
Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 and Cycle 5 (21 days per cycle)
Dose Verification: Clearance (Cl)
Time frame: Predose, end of infusion, 1.5 hours, 6 hours on Day 1, Day 2, Day 4, Day 8, Day 15, Day 22 predose in Cycle 1 (21 days per cycle)
Indication Expansion: Progression-free Survival (PFS)
Progression-free survival is defined as the time from the date of first study dose to disease progression or death, whichever comes first, as determined by Investigator per RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
Time frame: Up to approximately 3 years and 5 months
Indication Expansion: Duration of Response
Duration of response for responders with complete or partial response is defined as the time interval between the date of the earliest qualifying response and the date of progressive disease or death for any cause, whichever occurs earlier as determined by Investigator per RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
Time frame: Up to approximately 3 years and 5 months
Indication Expansion: Clinical Benefit Rate
Clinical benefit rate is defined as the percentage of participants in specific tumor types reaching confirmed CR, PR and durable stable disease (SD; at ≥ 24 weeks) in accordance with RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
Time frame: Up to approximately 3 years and 5 months
Indication Expansion: Overall Survival
Overall survival is defined as the time from the date of the first study dose to death. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
Time frame: Up to approximately 3 years and 5 months
Indication Expansion: Disease Control Rate
Disease control rate is defined as the percentage of participants reaching CR, PR, and SD according to RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
Time frame: Up to approximately 3 years and 5 months
Number of Participants With Positive Anti-drug Antibody (ADA) Status to Tislelizumab
Time frame: Up to approximately 23 months
A total of 300 participants were treated with at least 1 dose of tislelizumab. This was a single arm study with 3 parts: dose verification, pharmacokinetic (PK) sub-study, and indication expansion.
| Milestone | Tislelizumab |
|---|---|
| Started | 20 |
| Completed | 4 |
| Not completed | 16 |
| Withdrew: Death | 15 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Tislelizumab |
|---|---|
| Started | 57 |
| Completed | 16 |
| Not completed | 41 |
| Withdrew: Death | 35 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Other not specified | 1 |
| Milestone | Tislelizumab |
|---|---|
| Started | 223 |
| Completed | 54 |
| Not completed | 169 |
| Withdrew: Death | 152 |
| Withdrew: Withdrawal by subject | 10 |
| Withdrew: Lost to follow-up | 7 |
Number of participants with adverse events (AEs) and serious adverse events (SAEs), as defined per NCI-CTCAE Version 4.03, including physical examination, electrocardiograms and laboratory assessments
| Participants | Dose Verification | PK Sub-study |
|---|---|---|
| At least one treatment-emergent adverse event (TEAE) | 20 | 54 |
| TEAE Grade 3 of higher | 9 | 21 |
| Serious adverse event | 4 | 14 |
Recommended dose of tislelizumab for indication cohorts based on safety and tolerability
| milligrams | Dose Verification |
|---|---|
| Dose Verification: Recommended Dose of Tislelizumab | 200 |
Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter final manufacturing process (FMP) were evaluated
| µg/mL*day | PK Sub-study |
|---|---|
| 500L-FMP | 1113.9 (997.6 to 1244) |
| 2000L-FMP | 1108 (985.2 to 1246) |
Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter final manufacturing process (FMP) were evaluated
| µg/mL*day | PK Sub-study |
|---|---|
| 500L-FMP | 810.2 (746.0 to 879.9) |
| 2000L-FMP | 801.7 (740.8 to 867.5) |
Pharmacokinetics from products derived from two manufacturing scales at 500 liter and 2000 liter FMP were evaluated
| µg/mL | PK Sub-study |
|---|---|
| 500L-FMP | 77.3 (73.6 to 81.2) |
| 2000L-FMP | 75.7 (70.7 to 81.0) |
Objective response rate (ORR) is defined as the percentage of participants who achieved objective tumor response (complete response or partial response) according to RECIST Version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
| Percentage of participants | Tislelizumab |
|---|---|
| NSCLC | 17.9 (8.9 to 30.4) |
| Melanoma | 17.6 (6.8 to 34.5) |
| ESCC | 7.7 (0.9 to 25.1) |
| GC | 16.7 (4.7 to 37.4) |
| UC | 18.2 (5.2 to 40.3) |
| NPC | 47.6 (25.7 to 70.2) |
| RCC | 9.5 (1.2 to 30.4) |
| HCC | 16.7 (3.6 to 41.4) |
| MSI-H/dMMR | 25.0 (7.3 to 52.4) |
| Other | 9.5 (3.6 to 19.6) |
| µg/mL*day | Dose Verification |
|---|---|
| Cycle 1 | 600.1 ± 144.5 |
| Cycle 5 | 1122 ± 352 |
| µg/mL | Dose Verification |
|---|---|
| Cycle 1 | 67.8 ± 12.8 |
| Cycle 5 | 131 ± 37.7 |
| µg/mL | Dose Verification |
|---|---|
| Cycle 1 | 15.8 ± 4.73 |
| Cycle 5 | 31.4 ± 9.55 |
| Days | Dose Verification |
|---|---|
| Cycle 1 | 13.3 ± 2.95 |
| Cycle 5 | 16.9 ± 3.79 |
| Liters/day | Dose Verification |
|---|---|
| Dose Verification: Clearance (Cl) | 0.247 ± 0.0918 |
Progression-free survival is defined as the time from the date of first study dose to disease progression or death, whichever comes first, as determined by Investigator per RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
| Months | Tislelizumab |
|---|---|
| NSCLC | 4.0 (2.1 to 8.1) |
| Melanoma | 2.2 (2.0 to 6.1) |
| ESCC | 2.1 (2.0 to 4.2) |
| GC | 2.1 (1.9 to 4.0) |
| UC | 2.1 (2.0 to 4.3) |
| NPC | 8.2 (4.2 to 11.4) |
| RCC | 4.1 (2.1 to 10.4) |
| HCC | 4.0 (2.1 to 12.4) |
| MSI-H/dMMR | 6.1 (2.0 to 15.3) |
| Other | 2.3 (2.2 to 2.8) |
Duration of response for responders with complete or partial response is defined as the time interval between the date of the earliest qualifying response and the date of progressive disease or death for any cause, whichever occurs earlier as determined by Investigator per RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
| Months | Tislelizumab |
|---|---|
| NSCLC | 30.4 (8.3 to 30.4) |
| Melanoma | 12.5 (4.2 to NA) |
| ESCC | NA (13.8 to NA) |
| GC | NA (13.9 to NA) |
| UC | NA (8.3 to NA) |
| NPC | 8.8 (3.9 to 14.8) |
| RCC | NA (4.4 to NA) |
| HCC | NA (8.3 to NA) |
| MSI-H/dMMR | NA (5.1 to NA) |
| Other | NA (8.3 to NA) |
Clinical benefit rate is defined as the percentage of participants in specific tumor types reaching confirmed CR, PR and durable stable disease (SD; at ≥ 24 weeks) in accordance with RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
| Percentage of participants | Tislelizumab |
|---|---|
| NSCLC | 33.9 (21.8 to 47.8) |
| Melanoma | 32.4 (17.4 to 50.5) |
| ESCC | 15.4 (4.4 to 34.9) |
| GC | 25.0 (9.8 to 46.7) |
| UC | 27.3 (10.7 to 50.2) |
| NPC | 61.9 (38.4 to 81.9) |
| RCC | 38.1 (18.1 to 61.6) |
| HCC | 38.9 (17.3 to 64.3) |
| MSI-H/dMMR | 50.0 (24.7 to 75.3) |
| Other | 22.2 (12.7 to 34.5) |
Overall survival is defined as the time from the date of the first study dose to death. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
| Months | Tislelizumab |
|---|---|
| NSCLC | 22.1 (10.1 to 33.5) |
| Melanoma | 11.8 (7.0 to 24.2) |
| ESCC | 4.8 (3.6 to 8.5) |
| GC | 4.7 (2.4 to 14.6) |
| UC | 4.3 (2.1 to 22.9) |
| NPC | 25.0 (11.7 to NA) |
| RCC | 19.8 (8.0 to 24.3) |
| HCC | 25.1 (5.5 to NA) |
| MSI-H/dMMR | 19.4 (4.2 to NA) |
| Other | 9.0 (4.8 to 13.4) |
Disease control rate is defined as the percentage of participants reaching CR, PR, and SD according to RECIST version 1.1. Indication expansion includes participants from all parts in the following indications: non-small cell lung cancer (NSCLC), melanoma, esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), urothelial carcinoma (UC), nasopharyngeal carcinoma (NPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and other tumor types.
| Percentage of participants | Tislelizumab |
|---|---|
| NSCLC | 55.4 (41.5 to 68.7) |
| Melanoma | 38.2 (22.2 to 56.4) |
| ESCC | 34.6 (17.2 to 55.7) |
| GC | 25.0 (9.8 to 46.7) |
| UC | 40.9 (20.7 to 63.6) |
| NPC | 81.0 (58.1 to 94.6) |
| RCC | 52.4 (29.8 to 74.3) |
| HCC | 55.6 (30.8 to 78.5) |
| MSI-H/dMMR | 50.0 (24.7 to 75.3) |
| Other | 31.7 (20.6 to 44.7) |
| Participants | Tislelizumab |
|---|---|
| Treatment-emergent | 43 |
| Treatment-boosted | 2 |
| Treatment-induced | 41 |
Collected over Up to 30 days after the last dose of study treatment; Up to approximately 3 years and 5 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tislelizumab | 202/300 (67.3%) | 85/300 (28.3%) | 277/300 (92.3%) |
| Event | Tislelizumab |
|---|---|
| PneumoniaInfections and infestations | 11/300 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 6/300 |
| DeathGeneral disorders | 5/300 |
| Intestinal obstructionGastrointestinal disorders | 4/300 |
| PyrexiaGeneral disorders | 3/300 |
| HyperuricaemiaMetabolism and nutrition disorders | 3/300 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/300 |
| Immune-mediated myocarditisCardiac disorders | 2/300 |
| DysphagiaGastrointestinal disorders | 2/300 |
| VomitingGastrointestinal disorders | 2/300 |
| Event | Tislelizumab |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 110/300 |
| Aspartate aminotransferase increasedInvestigations | 81/300 |
| Alanine aminotransferase increasedInvestigations | 71/300 |
| Blood bilirubin increasedInvestigations | 52/300 |
| ProteinuriaRenal and urinary disorders | 52/300 |
| Weight decreasedInvestigations | 50/300 |
| Gamma-glutamyltransferase increasedInvestigations | 47/300 |
| HypothyroidismEndocrine disorders | 45/300 |
| PyrexiaGeneral disorders | 39/300 |
| Bilirubin conjugated increasedInvestigations | 37/300 |
The Safety Analysis Set (SAS) included all participants who received ≥ 1 dose of tislelizumab; Safety analysis data are summarized for the overall population given that the same dose was applied, regardless of part assignment, as pre-specified in the clinical study report.
| Age, Continuous(Years) | Tislelizumab |
|---|---|
| Mean | 55.5 ± 11.48 |
| Sex: Female, Male(Participants) | Tislelizumab |
|---|---|
| Female | 93 |
| Male | 207 |
| Race/Ethnicity, Customized(Participants) | Tislelizumab |
|---|---|
| Chinese | 300 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Dec 2016 to primary completion in Dec 2018, 23 months.
Results were first posted in Nov 2023, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab